Physician profile
James Struble
NPI 1073663399
$2,809.38
in general payments reported to CMS, 2019-2025
28 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $709 · 2022: $878 · 2023: $509 · 2024: $359 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.67 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.61 | 2021-2024 | |
| Astellas Pharma US INC | $314.93 | 2021-2024 | Veozah |
| Daiichi Sankyo INC. | $256.13 | 2022-2024 | Injectafer |
| Amgen INC. | $234.35 | 2021-2025 | Evenity, Prolia, Prolia |
| Exeltis, USA INC. | $187.84 | 2021-2023 | Slynd |
| Radius Health, INC. | $171.47 | 2023-2025 | Tymlos |
| Biogen, INC. | $155.23 | 2025 | Zurzuvae |
| Organon LLC | $113.54 | 2022-2024 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.40 | 2021 | |
| Lilly USA, LLC | $75.86 | 2021-2025 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $64.26 | 2021-2023 | Trintellix |
| Pharmacosmos Therapeutics INC. | $64.07 | 2021-2023 | Monoferric |
| Sumitomo Pharma America, INC. | $63.69 | 2025 | Myfembree, Gemtesa |
| Axonics, INC. | $57.43 | 2022-2023 | Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $56.73 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $56.23 | 2021-2022 | |
| Hologic Sales and Service, LLC | $54.06 | 2024-2025 | Novasure, Myosure Tissue Removal Device |
| Pacira Pharmaceuticals Incorporated | $34.05 | 2025 | Exparel |
| Avion Pharmaceuticals | $23.30 | 2021 | |
| Ortho-Clinical Diagnostics, INC. | $21.49 | 2021 | |
| Mayne Pharma Commercial LLC | $19.64 | 2023 | |
| Therapeuticsmd, INC. | $16.81 | 2022 | |
| Scynexis, INC. | $15.01 | 2022 | |
| Pfizer INC. | $13.49 | 2024 | |
| Exact Sciences Corporation | $13.08 | 2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $12.70 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.56 | 2022 | |
| Molnlycke Health Care US, LLC | $10.42 | 2024 | Mepilex Border Post-Op Ag, Avance, Mepilex Border Post-Op |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Struble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.